Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

In an exclusive conversation with Outlook Business, the company’s Chief Sustainability Officer, Chris Leong, explains how ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced ...

"We couldn't be more excited to collaborate with Tempus and AstraZeneca given the potential of these models to improve patient outcomes." Tempus is a technology company advancing precision medicine ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in ...

Smaller biotechnology companies, and large pharmaceutical rivals including AstraZeneca Plc ... to be associated with a higher risk of a rare form of vision loss, according to an analysis by ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL ... The disease is a painful form of inflammatory arthritis caused by elevated levels of uric acid in ...

On March 17, competitor AstraZeneca announced "positive" phase ... On March 31, the company announced submission of New Drug Application for TransCon CNP in achondroplasia. They also remain ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...